troglitazone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| peroxisome proliferator activating receptor-gamma (PPAR-gamma) agonists, thiazolidinedione derivatives | 2767 | 97322-87-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.40 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 22.65 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 45 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.00 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 29, 1997 | FDA | PFIZER PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10BG01 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Thiazolidinediones |
| MeSH PA | D007004 | Hypoglycemic Agents |
| CHEBI has role | CHEBI:22586 | antioxidants |
| CHEBI has role | CHEBI:35526 | antidiabetic |
| CHEBI has role | CHEBI:35610 | antineoplastic agents |
| CHEBI has role | CHEBI:35620 | vasodilator agents |
| CHEBI has role | CHEBI:35623 | anticonvulsants |
| CHEBI has role | CHEBI:50249 | anticoagulants |
| CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
| CHEBI has role | CHEBI:83157 | EC 6.2.1.3 inhibitors |
| CHEBI has role | CHEBI:173084 | ferroptosis inhibitors |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.33 | acidic |
| pKa2 | 12.07 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Nuclear hormone receptor | AGONIST | EC50 | 6.27 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.08 | DRUG MATRIX | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
| Carbonic anhydrase 2 | Enzyme | IC50 | 6.01 | DRUG MATRIX | |||||
| Bile salt export pump | Transporter | IC50 | 5.57 | CHEMBL | |||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.02 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.98 | CHEMBL | |||||
| Aldose reductase | Enzyme | WOMBAT-PK | |||||||
| Tyrosine-protein phosphatase non-receptor type 1 | Enzyme | IC50 | 4.26 | CHEMBL | |||||
| Glycogen [starch] synthase, liver | Enzyme | WOMBAT-PK | |||||||
| Thromboxane-A synthase | Enzyme | IC50 | 5.53 | DRUG MATRIX | |||||
| Mitogen-activated protein kinase 1 | Kinase | IC50 | 5.91 | DRUG MATRIX | |||||
| UDP-glucuronosyltransferase 1-6 | Enzyme | Ki | 4.70 | CHEMBL | |||||
| Cytochrome P450 3A4 | Enzyme | Km | 3.21 | WOMBAT-PK | |||||
| Forkhead box protein M1 | Unclassified | Ki | 7.28 | CHEMBL | |||||
| Aldose reductase | Enzyme | IC50 | 5.69 | DRUG MATRIX | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 4.96 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.32 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.35 | CHEMBL | |||||
| Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.21 | CHEMBL | |||||
| Bile salt export pump | Transporter | IC50 | 4.97 | CHEMBL | |||||
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Enzyme | IC50 | 4.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020997 | VUID |
| N0000148466 | NUI |
| D00395 | KEGG_DRUG |
| 4020997 | VANDF |
| C0245514 | UMLSCUI |
| CHEBI:9753 | CHEBI |
| TDZ | PDB_CHEM_ID |
| CHEMBL408 | ChEMBL_ID |
| D000077288 | MESH_DESCRIPTOR_UI |
| DB00197 | DRUGBANK_ID |
| 2693 | IUPHAR_LIGAND_ID |
| 6851 | INN_ID |
| I66ZZ0ZN0E | UNII |
| 5591 | PUBCHEM_CID |
| 203715 | RXNORM |
| 5640 | MMSL |
| 9149 | MMSL |
| d04122 | MMSL |
| 006355 | NDDF |
| 109085002 | SNOMEDCT_US |
| 386967007 | SNOMEDCT_US |
Pharmaceutical products:
None